ATMI Invests in Sterile Fill and Connector Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ATMI Invests in Sterile Fill and Connector Technology



ATMI, a provider of single-use bioprocess solutions, has invested in sterile connector and sterile fill technology developed by Medical Instill Technologies (Medinstill), a provider of transfer and packaging solutions for high purity fluids at unmatched safety levels.

The investments focus on the INTACT family of products developed by Medinstill. These technologies will be deployed in sterile filling, sterile multiple-dose dispensing, sterile transfer, and packaging sterilization solutions.

In other news, ATMI has introduced a line of pyrogen-free vials in collaboration with Disposable Lab, a Bordeaux, France contract manufacturing organization

Source: ATMI

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here